Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,88
KB-0,72
PKN55,7255,740,54
Msft272,6272,62-2,49
Nokia4,324,3231,70
IBM125,18125,191,23
Mercedes-Benz Group AG69,3669,380,14
PFE40,4440,450,89
20.03.2023 16:43:01
Indexy online
AD Index online
select
AD Index online
 

  • 20.03.2023 16:42:35
Biogen Idec (BIIB.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
263,74 0,22 0,58 225 173
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 20.03.2023
Popis společnosti
Obecné informace
Název společnostiBiogen Inc
TickerBIIB
Kmenové akcie:Ordinary Shares
RICBIIB.O
ISIN-
Prioritní akciePreference Shares Series A
Prioritní akciePreference Shares Series X
Poslední známé roční výsledky31.12.2022
Poslední známé čtvrtletní výsledky31.12.2022
Počet zaměstnanců k 31.12.2022 8 725
Akcie v oběhu k 14.02.2023 144 485 646
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice225 Binney Street
MěstoCAMBRIDGE
PSČ02142
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon17 814 642 000
Fax13026365454

Business Summary: Biogen Inc. is a global biotechnology company. The Company is focused on discovering, developing and delivering therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. It is focused on advancing its pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. It is also advancing its mid-to-late stage programs, including zuranolone for major depressive disorder (MDD) and postpartum depression (PPD), BIIB080 for Alzheimer's disease, tofersen for amyotrophic lateral sclerosis (ALS) and both litifilimab and dapirolizumab pegol for certain forms of lupus.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2022, Biogen Inc revenues decreased 7% to $10.17B. Net income increased 96% to $3.05B. Revenues reflect Rest of World segment decrease of 10% to $4.52B, United States segment decrease of 9% to $3.47B. Net income reflects FV Adjustments of Financial Investments decrease of 68% to $264.7M (expense), Impairment of Intangibles Excl Goodwill decrease of 81% to $119.6M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biopharmaceuticals
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Biological Product (except Diagnostic) Manufacturing
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 20.03.2023
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorChristopher Viehbacher6214.11.202214.11.2022
Chief Financial Officer, Executive Vice PresidentMichael McDonnell5815.08.202015.08.2020
Chief Human Resource Officer, Executive Vice PresidentGinger Gregory5417.07.201717.07.2017
Executive Vice President, Chief Legal Officer and SecretarySusan Alexander6530.01.2006
Executive Vice President, Pharmaceutical Operations and TechnologyAlphonse Galdes6901.10.201901.10.2019
Executive Vice President, Head of Alzheimers Disease and Dementia Business UnitRachid Izzar47
Executive Vice President - Head of DevelopmentPriya Singhal-05.01.202305.01.2023
Senior Vice President, Chief Accounting OfficerRobin Kramer5619.11.2018
Senior Vice President, Head of Investor RelationsCharles Triano-10.04.202310.04.2023